Hans-Peter Hartung, Lawrence Steinman, Douglas S Goodin, Giancarlo Comi, Stuart Cook, Massimo Filippi, Paul O'Connor, Douglas R Jeffery, Ludwig Kappos, Robert Axtell, Volker Knappertz, Timon Bogumil, Susanne Schwenke, Ed Croze, Rupert Sandbrink, Christopher Pohl
IMPORTANCE: High serum levels of interleukin 17F (IL-17F) at baseline have been associated with suboptimal response to interferon beta in patients with relapsing-remitting multiple sclerosis. OBJECTIVE: To further investigate the role of IL-17F in predicting treatment response to interferon beta-1b in patients with relapsing-remitting multiple sclerosis using the Singulex Erenna IL-17F immunoassay. DESIGN, SETTING, AND PATIENTS: Serum samples were analyzed from 239 randomly selected patients treated with interferon beta-1b, 250 μg, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study...
August 2013: JAMA Neurology